Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

Abstract Background A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-
like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

Background Obesity is a major risk factor for many leading causes of illness and death
worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …